What is the role of Bremelanotide (generic name) in treating premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) in psychiatry?

Bremelanotide for Hypoactive Sexual Desire Disorder in Premenopausal Women

Bremelanotide is an FDA-approved, second-line treatment option for premenopausal women with hypoactive sexual desire disorder (HSDD), administered as a 1.75 mg subcutaneous injection as needed approximately 45 minutes before sexual activity, with demonstrated efficacy in improving sexual desire and reducing distress, though flibanserin remains the first-line pharmacologic option. 1

FDA-Approved Status and Mechanism

• Bremelanotide is FDA-approved specifically for acquired, generalized HSDD in premenopausal women 1, 2
• It functions as a melanocortin receptor-4 agonist, distinguishing it mechanistically from flibanserin's serotonergic action 3, 4
• The medication is self-administered subcutaneously using an autoinjector on an as-needed basis, approximately 45 minutes prior to anticipated sexual activity 3

Position in Treatment Algorithm

For premenopausal women with HSDD, the American College of Obstetricians and Gynecologists recommends flibanserin (100 mg daily at bedtime) as first-line pharmacotherapy, with bremelanotide as an FDA-approved alternative option. 1

The treatment hierarchy is:

• First-line: Flibanserin 100 mg daily at bedtime 1
• Alternative first-line: Bremelanotide 1.75 mg subcutaneous injection as needed 1
• Second-line/off-label: Bupropion or buspirone for patients with contraindications or intolerance to first-line options 1

Clinical Efficacy Data

Bremelanotide demonstrates statistically significant improvements in both coprimary endpoints:

• Sexual desire improvement: Increases in Female Sexual Function Index-desire domain scores ranging from 0.30 to 0.42 points compared to placebo (p<0.001) 5
• Distress reduction: Decreases in Female Sexual Distress Scale scores of -0.29 to -0.37 points compared to placebo (p≤0.005) 5
• These improvements were consistent across multiple subgroups including different age ranges, BMI categories, baseline testosterone levels, and regardless of hormonal contraceptive use 6

The National Comprehensive Cancer Network notes that bremelanotide significantly improves sexual desire and reduces distress related to low sexual desire compared to placebo, though the clinical magnitude of benefit may be modest 2, 3

Prescribing Guidelines and Administration

Critical prescribing parameters:

• Maximum dosing: No more than 1 dose in 24 hours and no more than 8 doses per month 3
• Timing: Administer approximately 45 minutes before anticipated sexual activity 3
• Trial duration: Discontinue after 8 weeks if no clinical benefit is observed 3
• Route: Subcutaneous injection via autoinjector 3, 6

Safety Profile and Adverse Effects

The most common adverse effects include:

• Nausea: 39.9% of patients (most frequent adverse effect) 3
• Facial flushing: 20.4% of patients 3
• Headache: 11% of patients 3

Important safety considerations:

• Most treatment-emergent adverse events are mild to moderate in intensity and related to tolerability 5
• Bremelanotide has limited drug-drug interactions, including no clinically significant interactions with alcohol 3
• The safety profile is generally favorable compared to other pharmacologic options 5

Special Populations and Considerations

Cancer survivors: While bremelanotide has not been specifically studied in cancer survivors, the National Comprehensive Cancer Network guidelines suggest it may be an appropriate option for some premenopausal survivors with HSDD 2

Postmenopausal women: Bremelanotide is FDA-approved only for premenopausal women; for postmenopausal women with HSDD, consider off-label flibanserin or ospemifene if concurrent dyspareunia exists without history of estrogen-dependent cancers 1

Comparative Positioning vs. Flibanserin

Key differences favoring bremelanotide:

• As-needed dosing provides flexibility compared to flibanserin's daily administration 3
• Different mechanism of action offers alternative for flibanserin non-responders 3, 4
• No alcohol interaction restrictions unlike flibanserin 3

Key differences favoring flibanserin:

• Designated as first-line option by ACOG guidelines 1
• Daily dosing may provide more consistent baseline improvement 1

Common Pitfalls and Caveats

• Modest clinical benefit: While statistically significant, the absolute clinical improvement may be limited, requiring realistic patient expectations 3
• Nausea management: The 39.9% incidence of nausea is substantial and should be discussed during counseling 3
• Limited data in specific populations: Evidence in cancer survivors and postmenopausal women is lacking 1, 2
• Cost considerations: As a newer branded medication, cost may be prohibitive for some patients compared to off-label alternatives
• Discontinuation criteria: Patients must be counseled to discontinue after 8 weeks without benefit to avoid unnecessary exposure and cost 3